Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
White Paper Declaration

NKTR price history

Date	Close	Change	Chg%	Open	Min.	Max.
2022-09-30	73.54	-1.05	-1.41	74.59	72.34	75.53
2022-09-30	74.12	-1.26	-1.67	75.38	72.66	75.67
2022-09-30	75.28	0.89	1.20	74.39	72.78	75.87
2022-09-30	73.53	2.51	3.53	71.02	69.92	74.57
2022-09-30	72.21	0.54	0.75	71.67	69.65	74.2
2022-09-30	72.81	0.26	0.36	72.55	71.27	75.0
2022-09-30	75.44	0.64	0.86	74.8	74.76	76.67
2022-09-30	75.31	0.29	0.39	75.02	74.37	76.19
2022-09-30	75.17	1.46	1.98	73.71	73.71	75.19
2022-09-30	74.69	0.23	0.31	74.46	73.75	75.86
2022-09-30	75.84	3.23	4.45	72.61	72.61	76.4
2022-09-30	73.02	2.50	3.55	70.52	70.52	73.63
2022-09-30	72.88	1.78	2.50	71.1	71.1	73.57
2022-09-30	72.04	1.67	2.37	70.37	70.15	72.63
2022-09-30	70.22	0.44	0.63	69.78	66.39	70.84

Mobile app

Full trading account functionality: order execution and cancellation, stop-loss and take-profit setup, transaction history, deposits and withdrawals

iOS

4,7

12 127 reviews

Android

4,1

9 795 reviews

Trade Nektar Therapeutics - NKTR stock price

NKTR price history

NKTR price history

Mobile app